Osmotica Pharmaceuticals plc (NASDAQ:OSMT) is reporting second quarter financial results on Tuesday 11th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, OSMT is expected to report 2Q20 loss of $ 0.12 per share from revenue of $ 40.83 million.
For the full year, analysts anticipate top line of $ 172.22 million, while looking forward to loss of $ 0.59 per share bottom line.
Previous Quarter Performance
Osmotica Pharmaceuticals plc reported loss for the first quarter of $ 0.05 per share, from the revenue of $ 48.65 million. The quarterly revenues reduced 21.11 percent compared with the same quarter last year. Street analysts expected Osmotica Pharmaceuticals plc to report loss of $ 0.14 per share on revenue of $ 45.47 million for the first quarter. The bottom line results beat street analysts by $ 0.09 or 64.29 percent, at the same time, top line results outshined analysts by $ 3.18 million or 6.99 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Osmotica Pharmaceuticals plc
Stock Performance
According to the previous trading day, closing price of OSMT was $ 5.75, representing a 112.96 % increase from the 52 week low of $ 2.70 and a 40.54 % decrease over the 52 week high of $ 9.67.
The company has a market capital of $ 337.87 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”OSMT” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 10th July 2020, maintained by SunTrust Robinson Humphrey at Buy rating, with $ 11.00 target price.
Conference Call
Osmotica Pharmaceuticals plc will be hosting a conference call at 4:30 PM eastern time on 11th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.osmotica.com
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The companys promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinsons and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides womens health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos.
